FDA clears Riverain's updated chest CAD technology

Justine Varieur Cadet | | Health Exec | EMR/EHR
The FDA has granted approval for Riverain Medical’s newest version of the OnGuard chest x-ray computer-aided detection (CAD) technology.

OnGuard identifies solitary pulmonary nodules that may represent early-stage lung cancer on an existing chest x-ray, according to the Dayton, Ohio-based company. Because OnGuard utilizes the existing digital chest x-ray, Riverain added that there is no additional radiation dose, patient procedure, hardware or standalone workstation needed to integrate the CAD technology into a radiology department.

Justine Varieur Cadet

Related Content

Christmas ransomware exposed over 300K patient records to dark web
Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care

Around the web

Cardiovascular Business
Why electrophysiologists needed a champion in Washington

Heart Rhythm Society President Kenneth A. Ellenbogen, MD, detailed a new advocacy group focused on improving EP reimbursements, patient care and access. “If you’re not at the table, you’re on the menu," he said.

Cardiovascular Business
Reimbursement update: What hospitals need to know about new Medicare payments for cardiac CT

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Cardiovascular Business
Stryker acquires Inari Medical for $4.9B

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.